A PHARMACEUTICAL COMPOSITION COMPRISING A PHARMACEUTICALLY EFFECTIVE AMOUNT OF AN INSULIN SENSITIZER AGENT AND A PHARMACEUTICALLY EFFECTIVE A MOUNT OF AN FBPASE INHIBITOR

摘要

The instant invention is a combination therapy and a composition for the treatment for diabetes and diseases responding to improved glycemic control or to improve peripheral insulin sensitivity. The therapy requires administration of a insulin sensitizer agent, e.g. PPAR γ agonist, RXR ligand, or another agent known to enhance insulin action and an FBPase inhibitor either together or at a different time such that improved glycemic control is achieved In another aspect of the invention, the combined therapy results in decreases in hepatic glucose output beyond that observed for glucose lowering doses of the insulin sensitizer agent Furthermore, the combined therapy can result in improvements in insulin resistance and/or insulin secretion beyond that observed for either agent alone Yet another aspect of the invention is that a combination therapy achieves similar benefits as observed with one or the other therapies alone but at significantly lower doses. The present invention relates to methods and compositions for treating an animal having NIDDM or a condition associated with insulin resistance by administering to the animal a composition containing a pharmaceutically effective amount of an agent that enhances insulin sensitivity and a pharmaceutically effective amount of an FBPase inhibitor. The compositions of this invention are adapted to cure, improve or prevent one or more symptoms of NIDDM. A preferred drug combination will have high potency and low toxicity. Another object of the invention relates to methods and compositions for treating insulin-requiring NIDDM patients. The combination therapy decreases the insulin requirement and associated safety risks. Another object of the invention relates to methods and compositions for treating diseases or conditions characterized by insulin resistance, including obesity, hypertension, impaired glucose tolerance, and polycystic ovarian syndrome. Individuals with syndrome X, renal disease, or pancreatitis are also effectively treated with the combination therapy.